Biomarker Changes and Anxiolytic Effects-Phase 2

Inclusion Criteria: * Adults ages 18-50 who meet Diagnostic Statistical Manual (DSM)-5 criteria for GAD as the primary psychiatric diagnosis * No more than one failed therapeutic trial of an FDA approved medication for the treatment of GAD * Score of\>14 on the Hamilton Anxiety Rating Scale at both screening and baseline * At least a 4 (moderate) on the Clinical Global Impressions Severity Scale at both screening and baseline * Females of potential childbearing status must use adequate contraceptive precautions. Exclusion Criteria: * Unwilling/unable/unsafe to stop psychotropic medications (if on any) for the duration of the study * Inability to refrain from acetaminophen, alcohol or other potentially hepatotoxic substances * History of liver disease or current liver disease or clinically significant elevation in serum liver chemistries * Unstable medical or neurological condition * Positive urine drug screen for substances of abuse * Active substance abuse/dependence * Lifetime history of a psychotic disorder, bipolar disorder, PTSD or Obsessive Compulsive Disorder * Any significant risk for self-harm or suicidality as determined by the principal investigator or suicide attempt within the last 6 months * Psychotherapy newly instituted during the 6 weeks leading up to enrollment in the study. Subjects established in psychotherapy without change during the course of the study may participate * Montgomery-Asberg Depression Rating Scale (MADRS) \> 17 (moderate or severe depressive symptoms)